Vistagen Therapeutics, Inc. - VTGN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | ORBIMED ADVISORS LLC | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | ORBIMED CAPITAL LLC | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | TCG Crossover GP I, LLC | 1.8% | 740,101 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | TCG Crossover Fund I, L.P. | 1.8% | 740,101 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | TCG Crossover GP II, LLC | 5.1% | 2,220,303 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | TCG Crossover Fund II, L.P. | 5.1% | 2,220,303 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Chen Yu | 6.7% | 2,960,404 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 9.9% | 4,244,590 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 9.9% | 4,244,590 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 9.9% | 4,244,590 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Michael Kramarz | 9.9% | 4,244,590 | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover GP I, LLC | 2.6% | 1,025,007 | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover Fund I, L.P. | 2.6% | 1,025,007 | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover GP II, LLC | 7.6% | 3,075,022 | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover Fund II, L.P. | 7.6% | 3,075,022 | View |
| May 15, 2026 | SCHEDULE 13G/A | Chen Yu | 9.99% | 4,100,029 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.